GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions

Simply Wall St.

07/07

GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2649564670"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649564670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649564670?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-07 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649564670","market":"us","top_or_hot":-1,"title":"GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions","media":"Simply Wall St.","content":"<div>\n<p>GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-following-trial-miss-and-cl\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRAIL (GRAL) Could Be 5% Overvalued Following Trial Miss And Class Actions\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-07-07 08:32</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-following-trial-miss-and-cl\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-following-trial-miss-and-cl\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-following-trial-miss-and-cl","article_id":"2649564670","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-following-trial-miss-and-cl","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649564670","pubTimestamp":1783384358,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of securities class action lawsuits.\nSee our latest analysis for GRAIL.\nSince that disclosure and the resulting securities class actions, GRAIL’s share price has seen a 14.95% 1 month share price return and a 40.28% 3 month share price return. The 1 year total shareholder return is 53.73%, suggesting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc.","BK4139":"生物科技"},"translate_title":"在试验失败和集体诉讼后，GRAIL(GRAL)的估值可能被高估5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1.5},"content_text":"GRAIL (GRAL) stock has been in focus after the company disclosed that its NHS-Galleri trial did not meet the primary endpoint in reducing late stage cancers, triggering sharp losses and a wave of securities class action lawsuits. See our latest analysis for GRAIL. Since that disclosure and the resulting securities class actions, GRAIL’s share price has seen a 14.95% 1 month share price return and a 40.28% 3 month share price return. The 1 year total shareholder return is 53.73%, suggesting recent momentum has picked up after earlier setbacks. If you are reassessing your exposure to healthcare and cancer screening, it can help to widen the search to other focused healthcare AI opportunities using the 40 healthcare AI stocks After GRAIL’s sharp drop on the trial news and its strong rebound since, the stock now sits slightly above the average analyst target. The key question is where a reasonable view of fair value falls between the recent price action and that range of estimates. AdvertisementMost Popular Narrative: 4.5% Overvalued GRAIL currently trades at $68.95, slightly above the most followed narrative fair value of $66, which is built using a 7.19% discount rate and detailed earnings and margin assumptions.  Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.  Read the complete narrative. The core narrative for GRAIL leans heavily on fast revenue expansion, a sharp margin reset and a premium future earnings multiple. Curious what combination of growth, profitability shift and discount rate is needed to support a fair value so close to today’s price and still judge the stock as overvalued? Result: Fair Value of $66 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, for GRAIL the narrative can quickly shift if regulatory decisions around Galleri or ongoing securities class action developments begin to weigh on adoption and investor confidence. Find out about the key risks to this GRAIL narrative. Next Steps With sentiment around GRAIL clearly split between concern and optimism, it makes sense to move quickly, review the underlying data, and focus on the 2 key rewards and 4 important warning signs. Looking for more investment ideas beyond GRAIL? Do not stop at GRAIL alone; broaden your watchlist with other stocks that match clear, data driven criteria so you are not relying on a single story.  Target resilient income by reviewing companies with strong payouts and stability using the 8 dividend fortresses Spot potential mispricings by scanning for quality stocks trading below their assessed value through the 41 high quality undervalued stocks Get ahead of the crowd by zeroing in on underfollowed companies with solid fundamentals through the screener containing 18 high quality undiscovered gems   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}